Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation
Purpose. We assessed the clinical outcomes and toxicities following hypofractionation with helical tomographic intensity-modulated radiotherapy technology (tomotherapy) in patients with stage III non-small cell lung cancer (NSCLC) who were not candidates for surgery or concurrent chemoradiation. Met...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2020/9168424 |
id |
doaj-b2afc5eb8ebd4227858231ab4ba7062e |
---|---|
record_format |
Article |
spelling |
doaj-b2afc5eb8ebd4227858231ab4ba7062e2020-11-25T03:04:30ZengHindawi LimitedBioMed Research International2314-61332314-61412020-01-01202010.1155/2020/91684249168424Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent ChemoradiationJing Li0Hongqi Li1Yingjie Wang2Junyang Liu3Xuan Wang4Haifeng Pang5Dongshu Chang6Yupeng Di7Gang Ren8Ping Li9Yong Wang10Chen Liu11Xiao Chen12Xiaoli Kang13Tingyi Xia14Medical School of Chinese PLA, No. 28 Fuxing Road, Beijing 100853, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaDepartment of Radiation Oncology, Airforce Medical Center, PLA, No. 30 Fucheng Road, Beijing 100142, ChinaMedical School of Chinese PLA, No. 28 Fuxing Road, Beijing 100853, ChinaPurpose. We assessed the clinical outcomes and toxicities following hypofractionation with helical tomographic intensity-modulated radiotherapy technology (tomotherapy) in patients with stage III non-small cell lung cancer (NSCLC) who were not candidates for surgery or concurrent chemoradiation. Methods. Forty-three patients with stage III NSCLC who were treated between 2011 and 2017 were enrolled. The prescription doses for gross target volume and clinical target volume were 70 Gy and 60 Gy (respectively) delivered in 15–25 fractions over 3–5 weeks. Results. The median overall survival (OS) time was 34.23 (range 11.33–99.33) months. The estimated 1-, 2-, and 3-year OS rates were 97.7%, 74.4%, and 55.9%, respectively; the corresponding progression-free survival (PFS) rates were 79.1%, 53.5%, and 36.1%, respectively. The local disease recurrence, regional disease recurrence, and distant metastasis rates at 3 years were 4.7%, 11.62%, and 55.81%, respectively. On multivariate analysis, dose regimen (<19 f vs. ≥19 f) was an independent prognostic factor affecting OS, PFS, and DM (p<0.05). Seven patients developed grade 1-2 acute radiation pneumonia (RP), 5 patients developed grade 1-2 late RP, while 3 patients developed grade 3 late RP. None of the patients developed grade 4-5 radiation lung injury. Conclusion. Tomotherapy may be an effective treatment option for patients with stage III NSCLC. It may be a viable alternative to surgery with lower incidence of side effects.http://dx.doi.org/10.1155/2020/9168424 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jing Li Hongqi Li Yingjie Wang Junyang Liu Xuan Wang Haifeng Pang Dongshu Chang Yupeng Di Gang Ren Ping Li Yong Wang Chen Liu Xiao Chen Xiaoli Kang Tingyi Xia |
spellingShingle |
Jing Li Hongqi Li Yingjie Wang Junyang Liu Xuan Wang Haifeng Pang Dongshu Chang Yupeng Di Gang Ren Ping Li Yong Wang Chen Liu Xiao Chen Xiaoli Kang Tingyi Xia Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation BioMed Research International |
author_facet |
Jing Li Hongqi Li Yingjie Wang Junyang Liu Xuan Wang Haifeng Pang Dongshu Chang Yupeng Di Gang Ren Ping Li Yong Wang Chen Liu Xiao Chen Xiaoli Kang Tingyi Xia |
author_sort |
Jing Li |
title |
Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation |
title_short |
Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation |
title_full |
Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation |
title_fullStr |
Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation |
title_full_unstemmed |
Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation |
title_sort |
outcomes of hypofractional tomotherapy in patients with stage iii nonsmall cell lung cancer who are not eligible for surgery or concurrent chemoradiation |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2020-01-01 |
description |
Purpose. We assessed the clinical outcomes and toxicities following hypofractionation with helical tomographic intensity-modulated radiotherapy technology (tomotherapy) in patients with stage III non-small cell lung cancer (NSCLC) who were not candidates for surgery or concurrent chemoradiation. Methods. Forty-three patients with stage III NSCLC who were treated between 2011 and 2017 were enrolled. The prescription doses for gross target volume and clinical target volume were 70 Gy and 60 Gy (respectively) delivered in 15–25 fractions over 3–5 weeks. Results. The median overall survival (OS) time was 34.23 (range 11.33–99.33) months. The estimated 1-, 2-, and 3-year OS rates were 97.7%, 74.4%, and 55.9%, respectively; the corresponding progression-free survival (PFS) rates were 79.1%, 53.5%, and 36.1%, respectively. The local disease recurrence, regional disease recurrence, and distant metastasis rates at 3 years were 4.7%, 11.62%, and 55.81%, respectively. On multivariate analysis, dose regimen (<19 f vs. ≥19 f) was an independent prognostic factor affecting OS, PFS, and DM (p<0.05). Seven patients developed grade 1-2 acute radiation pneumonia (RP), 5 patients developed grade 1-2 late RP, while 3 patients developed grade 3 late RP. None of the patients developed grade 4-5 radiation lung injury. Conclusion. Tomotherapy may be an effective treatment option for patients with stage III NSCLC. It may be a viable alternative to surgery with lower incidence of side effects. |
url |
http://dx.doi.org/10.1155/2020/9168424 |
work_keys_str_mv |
AT jingli outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT hongqili outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT yingjiewang outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT junyangliu outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT xuanwang outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT haifengpang outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT dongshuchang outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT yupengdi outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT gangren outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT pingli outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT yongwang outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT chenliu outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT xiaochen outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT xiaolikang outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation AT tingyixia outcomesofhypofractionaltomotherapyinpatientswithstageiiinonsmallcelllungcancerwhoarenoteligibleforsurgeryorconcurrentchemoradiation |
_version_ |
1715312263612596224 |